While the expected benefit of immunotherapy is limited in EGFR-mutant lung cancers, our study revealed that PS (0–1) was correlated with DCB of ICI therapies in EGFR-mutated lung cancers. The gene discussed is EGFR; the disease is lung carcinoma.